English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Reductions in N‐terminal pro‐B‐type natriuretic peptide ( NT ‐pro BNP ) concentrations after treatment have been associated with improved survival in people with congestive heart failure ( CHF ), but have not been reported in cats with  CHF .    Objectives  To evaluate changes in  NT ‐pro BNP  concentrations in cats with  CHF  after treatment and determine whether serial  NT ‐pro BNP  measurements provide prognostic information.    Animals  Thirty‐one client‐owned cats.    Methods  Prospective, observational study in cats with new onset  CHF  secondary to cardiomyopathy. Concentrations of  NT ‐pro BNP  were measured within 4 hours of admission to the hospital, on the day of discharge, and at re‐evaluation 7–10 days later.    Results  Median  NT ‐pro BNP  concentrations decreased significantly from admission (1,713 pmol/L [range, 160–3,784 pmol/L]) to discharge (902 pmol/L [range, 147–3,223 pmol/L]);  P  = .005) and from admission to re‐evaluation (1,124 pmol/L [range, 111–2,727 pmol/L];  P  = .024). Median survival time was 109 days (range, 1–709 days), with 5 cats still alive at the time of analysis. Cats with a larger percent decrease in  NT ‐pro BNP  from admission to discharge had a longer survival time ( P  = .048). Cats with evidence of active  CHF  at the time of re‐evaluation ( P  = .010) and cats whose owners had difficulty administering medications ( P  = .045) had shorter survival times.    Conclusions and clinical importance  Cats with a larger percent decrease in  NT ‐pro BNP  during hospitalization and no evidence of  CHF  at the time of re‐evaluation had longer survival times. Additional studies are needed to determine whether  NT ‐pro BNP  can help guide treatment in cats with  CHF .

Association between Survival Time and Changes in NT ‐pro BNP in Cats Treated for Congestive Heart Failure